Antibiotic susceptibility testing of *Mycoplasma hyopneumoniae* field isolates from Central Europe for fifteen antibiotics by microbroth dilution method

Orsolya Felde¹, Zsuzsa Kreizinger¹, Kinga Mária Sulyok¹, Veronika Hrivnák¹, Krisztian Kiss², Ákos Jerzsele³, Imre Biksi⁴, Miklós Gyuranecz¹,⁵*

1 Institute for Veterinary Medical Research, Centre for Agricultural Research, Hungarian Academy of Sciences, Budapest, Hungary, 2 SCG Diagnosztika Kft., Dégéyház, Hungary, 3 Department of Pharmacology and Toxicology, University of Veterinary Medicine, Budapest, Hungary, 4 Department and Clinic of Production Animals, University of Veterinary Medicine, Ullő, Hungary, 5 Department of Microbiology and Infectious Diseases, University of Veterinary Medicine, Budapest, Hungary

* m.gyuranecz@gmail.com

Abstract

*Mycoplasma hyopneumoniae* infections are responsible for significant economic losses in the swine industry. Commercially available vaccines are not able to inhibit the colonisation of the respiratory tract by *M. hyopneumoniae* absolutely, therefore vaccination can be completed with antibiotic treatment to moderate clinical signs and improve performances of the animals. Antibiotic susceptibility testing of *M. hyopneumoniae* is time-consuming and complicated; therefore, it is not accomplished routinely. The aim of this study was to determine the in vitro susceptibility to 15 different antibiotics of *M. hyopneumoniae* isolates originating from Hungarian slaughterhouses and to examine single-nucleotide polymorphisms (SNPs) in genes affecting susceptibility to antimicrobials. Minimum inhibitory concentration (MIC) values of the examined antibiotics against 44 *M. hyopneumoniae* strains were determined by microbroth dilution method. While all of the tested antibiotics were effective against the majority of the studied strains, high MIC values of fluoroquinolones (enrofloxacin 2.5 μg/ml; marbofloxacin 5 μg/ml) were observed against one strain (MycSu17) and extremely high MIC values of macrolides and lincomycin (tilmicosin, tulathromycin and lincomycin >64 μg/ml; gamithromycin 64 μg/ml; tylosin 32 μg/ml and tylvalosin 2 μg/ml) were determined against another, outlier strain (MycSu18). Amino acid changes in the genes *gyrA* (Gly81Ala; Ala83Val; Glu87Gly, according to *Escherichia coli* numbering) and *parC* (Ser80Phe/Tyr; Asp84Asn) correlated with decreased antibiotic susceptibility to fluoroquinolones and a SNP in the nucleotide sequence of the 23S rRNA (A2059G) was found to be associated with increased MIC values of macrolides. The correlation was more remarkable when final MIC values were evaluated. This study presented the antibiotic susceptibility profiles of *M. hyopneumoniae* strains circulating in the Central European region, demonstrating the high in vitro efficacy of the tested agents. The observed high MIC values correlated with the SNPs in the examined regions and support the relevance of susceptibility testing and directed antibiotic therapy.
Introduction

Mycoplasma hyopneumoniae is a member of the class Mollicutes [1] and the causative agent of porcine enzootic pneumonia [2]. M. hyopneumoniae infection affects especially growing pigs, causing significant economic losses in the swine industry worldwide, by chronic cough, growth retardation and predisposing animals to secondary infections [3–6]. Improvement of the management system and the environmental conditions of pig farms are essential parts of the control strategies just like vaccination and antibiotic treatment [4,7,8]. As vaccination alone is not always effective enough to prevent colonisation of the respiratory tract [9], antibiotic treatment might be necessary [4].

Mycoplasmas are resistant to antimicrobials that interfere with folic acid metabolism and cell wall synthesis, like sulphonamides, trimetoprim and the β-lactam class of antibiotics [5,10]. Macrolides, tetracyclines, fluoroquinolones, some aminoglycosides and aminocyclitols, lincosamides and pleuromutilins are active antimicrobial agents against M. hyopneumoniae [4,11]. However, studies have already drawn attention on the emergence of antibiotic resistance in M. hyopneumoniae to fluoroquinolones, macrolides, lincosamides and tetracyclines [12–14]. The decreased susceptibility may appear as a consequence of excessive medication [13,15,16]. The basics of in vitro susceptibility testing with microbroth dilution method were laid down almost 20 years ago [17], however, important points of standardisation are still absent.

Genomic changes (e.g. single-nucleotide polymorphism (SNP)) related to decreased effectiveness of certain antibiotics have been identified in previous publications [14,15,18,19]. Fluoroquinolones and macrolides are among the most frequently utilised antibiotic agents to control M. hyopneumoniae infection in Hungary [20,21]. The targets of the fluoroquinolone type antibiotics enrofloxacin and marbofloxacin, are topoisomerase enzymes (DNA gyrase and topoisomerase IV), which have essential role in bacterial DNA replication [15,18]. Emerging resistance to fluoroquinolones in mycoplasmas is usually due to transitions in the quinolone resistance-determining regions (QRDR) in genes encoding subunits of the topoisomerase enzymes (gyrA, gyrB, parC, parE) [19,22]. The majority of the substitutions, causing amino acid change and therefore increased MIC values, are observed in the parC gene (e.g. Ser80Phe, Ser80Tyr, Asp84Asn and Ala116Glu, according to Escherichia coli numbering) [15,18]. The amino acid change Ala83Val in gyrA gene was also described to be related to decreased susceptibility to enrofloxacin in M. hyopneumoniae [18]. Further amino acid substitutions in the gyrA gene observed in other Mycoplasma species were for example Gly81Ala or Glu87Gly [23,24]. According to the literature, 14-membered macrolides show low MIC against M. hyopneumoniae due to a G2057A transition in the 23S rRNA sequence [14]. In addition, adenosine→guanosine transition at nucleotide 2058 in the same region is frequently observed in association with increased resistance to 15- and 16-membered macrolides and lincosamides [14,25].

The aim of this study was to describe the antibiotic susceptibility profile of 44 M. hyopneumoniae strains isolated from Hungarian slaughterhouses in years 2015 and 2016, against 15 antimicrobial agents and to examine the genetic background of increased MIC values.

Materials and methods

Sample collection

Forty-four M. hyopneumoniae strains originating mainly from Hungary (n = 40), but also from Slovakia (n = 3) and the Czech Republic (n = 1) were tested in this study (S1 and S2 Tables). Hungarian slaughterhouses were visited between 2015 and 2016 for sampling. Ethical
approval and specific permission were not required for the study as all affected porcine lung samples, used for the isolation, were collected by the authors with the consent of the owners during routine diagnostic examinations of the carcasses in slaughterhouses. The affected lung samples were washed into Friis broth [26], and filtered through a 0.45 μm filter. The broth was diluted 30-fold and incubated for 4 weeks or until colour change at 37 °C. After the incubation period a 10-fold serial dilution was prepared, and incubated until colour change [27]. When colour change of the broth media occurred cultures were inoculated onto solid media and incubated at 37 °C and 5% CO₂ for 4–10 days, until visible colonies appeared. *Mycoplasma* strains were once filter-cloned, and DNA extraction was performed from the pure cultures using QIAamp DNA mini kit (Qiagen Inc., Hilden, Germany) according to the manufacturer’s instructions. Species-specific PCR test was accomplished to confirm the presence of *M. hyopneumoniae* [28]. To exclude the presence of other *Mycoplasma* species sequence analyses and BLAST search were carried out using the amplicons of a universal *Mycoplasmatales* PCR system targeting the 16S/23S rRNA intergenic spacer region [29]. PCR products were sequenced on ABI 3130XL genetic analyser (Applied Biosystems, Foster City, CA). Aliquots of purified cultures were stored frozen at -70 °C until usage.

**Antibiotic susceptibility testing**

The number of colour changing units (CCU) was determined by microbroth dilution method after four weeks of incubation [17]. Antimicrobial agents frequently used in Hungary [21] were selected for susceptibility tests: fluoroquinolones (enrofloxacin, marbofloxacin), aminoglycosides (gentamicin), aminocyclitols (spectinomycin), tetracyclines (oxytetracycline, doxycycline), macrolides (tylosin, tilmicosin, tyldolosin, tulathromycin, gamithromycin), pleuromutilins (tiamulin, valnemulin), phenicols (florfenicol) and lincosamides (lincomycin). Tyldolosin originated from ECO Animal Health Ltd., UK (Aivlosin), tulathromycin originated from Pfizer Inc., USA, and the rest of the products originated from VETRANAL, Sigma-Aldrich, Germany. The antibiotics were diluted and stored according to the recommendation of Hannan [17]. Stock solutions of 1 mg/ml were prepared in sterile distilled water, except the fluoroquinolones, tulathromycin, gamithromycin and florfenicol. Stock solutions of 1 mg/ml enrofloxacin and marbofloxacin were prepared in 0.1 M NaOH and stock solutions of 1 mg/ml tulathromycin, gamithromycin and florfenicol were prepared in 96% ethanol and sterile distilled water. Aliquots were stored at -70 °C until required, precipitation on thawing was checked before usage and dilutions for each test were freshly prepared. Twofold dilutions were made in the range 0.039–10 μg/ml for fluoroquinolones, pleuromutilins and doxycycline; 0.25–64 μg/ml for macrolides, gentamicin, spectinomycin, lincomycin and oxytetracycline; 0.125–32 μg/ml for florfenicol. Microbroth dilution test was accomplished using a 96-wells microtiter plate, containing growth control (bacterium culture in broth media), sterility control (broth media without bacterium culture) and end point control (sterile broth media adjusted to pH 6.8). By reason of the more pronounced colour change of the media, Mycoplasma Experience broth medium (Mycoplasma Experience Ltd., Bletchingley, United Kingdom) was applied for determining the number of CCU of strains and the susceptibility tests. The antibiotic susceptibility test was accomplished on 10⁴–10⁵ CCU/ml of the strains as recommended by Hannan [17]. All strains were tested in duplicates and all plates contained a duplicate of the type strain (NCTC 10110) as a quality control. MIC was established as the lowest antibiotic concentration where no colour change of the broth was observed as a consequence of the absence of bacterial metabolism. Initial MIC values were recorded when colour change of the broth media of the growth control was visible (4–14 days after inoculation) (S1 Table), and final MIC values were registered when no further colour change was observed.
MIC50 and MIC90 values were determined as the lowest concentrations that inhibited the growth of 50% or 90% of the strains [17].

Sequence analysis

Genetic markers correlating with antibiotic susceptibility in *M. hyopneumoniae* were examined in genes *gyrA*, *gyrB*, *parC*, *parE* and 23S rRNA [14,15,18,19]. While for the amplification of the genes *gyrA* and *gyrB* primers and heat profile were used according to Vicca *et al.* [18], for the amplification of genes *parC* and *parE*, primers and heat profile were used according to Le Carrou *et al.* [15], with modification of the annealing temperature to 56 °C. For the analysis of the 23S rRNA sequence the PCR conditions of Stakenborg *et al.* [14] were used with some modification of the annealing temperature to 56 °C and the following forward (5’ GAT GAG TAT TCT AAG GTG AGC GAG 3’) and reverse (5’ CAG TCA AAC TAC CCA CCA CG 3’) primers. PCR products were sequenced on ABI 3130XL genetic analyser (Applied Biosystems, Foster City, CA) and sequence analysis was performed by using Geneious software 10.2.3 (Biomatters Ltd.) [30]. The validity of SNPs was confirmed by manual examination of the assembled sequences. Numbering of nucleotide and amino acid positions is based on genes and proteins of *Escherichia coli* strain K-12 substrain MG1655 (GenBank accession number CP014225). Susceptibility profiles and correlating genetic markers were evaluated in relation with previously determined genotypes of the examined strains also [31].

Results

Antibiotic susceptibility profiles

The initial MIC values are evaluated and discussed throughout the study [17], however, differences were registered between initial and final MIC values in certain cases (S1 and S2 Tables). MIC values of the studied antimicrobial agents against the type strain (NCTC 10110) were consistent throughout the study (Table 1), and these results were mostly in accordance with previously defined values gained by microbroth dilution method (enrofloxacin 0.015–0.2 μg/ml, marbofloxacin 0.031 μg/ml, oxytetracycline 0.12–1 μg/ml, gentamicin 0.25–5 μg/ml, tylosin ≤0.015–0.06 μg/ml, tylvalosin 0.06 μg/ml, lincomycin 0.05–0.125 μg/ml, tiamulin 0.008–0.125 μg/ml, valnemulin ≤0.001–0.008 μg/ml) [11–13,32–34]. However, minor differences (two-fold increase or decrease) were observed in the MIC values against the type strain compared to earlier data in case of doxycycline (0.06–0.5 μg/ml), spectinomycin (0.5 μg/ml), tilmicosin (0.25–1 μg/ml) and florfenicol (0.25–0.5 μg/ml) [13,32–34]. Moreover, the MIC value of tulathromycin was noticeably higher (103 difference between MIC values) than that reported in the literature (≤0.001–0.002 μg/ml) [34]. Previously published MIC values for gamithromycin were not available at the time of the present study. The MIC ranges, the MIC50 and MIC90 values of each antibiotic against the examined strains, are recorded in Table 1.

As official breakpoints of antibiotics against *M. hyopneumoniae* are not standardized, MIC values were compared to previously published, unofficial breakpoints [11] in the present study. No correlation was found between antibiotic susceptibility profiles and earlier assigned genotypes of the examined strains [31].

The distribution of the MIC values of fluoroquinolones (enrofloxacin and marbofloxacin) showed one main peak coinciding with MIC50 value at the lowest antibiotic concentration (≤0.039 μg/ml), while the other values represented equipartition with the highest MIC values (2.5 μg/ml and 5 μg/ml, respectively) (Fig 1A and 1B). One strain (MycSu17) exceeded the unofficial breakpoint [11], with the MIC value of 2.5 μg/ml of enrofloxacin. All of the examined tetracyclines had low MIC values with MIC50 and MIC90 values of ≤0.25 μg/ml and 2 μg/ml of oxytetracycline; and 0.078 μg/ml and 0.312 μg/ml of doxycycline (Fig 1C and 1D). The
lowest examined concentration of gentamicin (≤0.25 μg/ml) was effective against most of the studied strains (Fig 1E). MIC\textsubscript{50} and MIC\textsubscript{90} values of spectinomycin were 2 μg/ml, with MIC 4 μg/ml being the highest detected value (Fig 1F). Five macrolides were tested (Fig 1G–1K), out of which tilmicosin showed a Gaussian distribution with 2 μg/ml and 4 μg/ml MIC\textsubscript{50} and MIC\textsubscript{90} values, respectively. One main peak at the lowest antibiotic concentration (≤0.25 μg/ml) was observed in the MIC values of tylosin and tylvalosin against the examined strains. MIC\textsubscript{50} values of gamithromycin and tulathromycin were 0.5 μg/ml, while MIC\textsubscript{90} values were 2 μg/ml and 1 μg/ml, respectively. Both MIC\textsubscript{50} and MIC\textsubscript{90} values of lincomycin coincided with the lowest examined antibiotic concentration (≤0.25 μg/ml) (Fig 1L). For all macrolides and for lincomycin high MIC values (>64 μg/ml of tilmicosin and tulathromycin; 64 μg/ml of gamithromycin; 32 μg/ml of tylosin; 2 μg/ml of tylvalosin; and >64 μg/ml of lincomycin) were detected against an outlier strain (MycSu18). Both studied pleuromutilins had low MIC values (Fig 1M and 1N). The MIC\textsubscript{50} and MIC\textsubscript{90} values of valnemulin were ≤0.039 μg/ml, while that of tiamulin ≤0.039 μg/ml and 0.078 μg/ml. MIC\textsubscript{50} and MIC\textsubscript{90} values of florfenicol were 1 μg/ml and 2 μg/ml (Fig 1O).

**Single-nucleotide polymorphisms correlating with decreased antibiotic susceptibility**

High MIC values of fluoroquinolones, macrolides and lincosamides, exceeding the unofficial breakpoints [11] were found in some cases (e.g. MycSu17-18). Both synonymous and non-

---

**Table 1. MIC values against the type strain and summary of MIC ranges, MIC\textsubscript{50} and MIC\textsubscript{90} values (μg/ml) against the *M. hyopneumoniae* strains involved in this study.**

| Antimicrobial Class | NCTC 10110 initial | NCTC 10110 final | Range initial | Range final | MIC\textsubscript{50} initial | MIC\textsubscript{50} final | MIC\textsubscript{90} initial | MIC\textsubscript{90} final |
|---------------------|-------------------|-------------------|---------------|-------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
| Fluoroquinolones    |                   |                   |               |             |                             |                             |                             |                             |
| Enrofloxacin        | ≤0.039            | 0.078             | ≤0.039–2.5    | ≤0.039–5    | ≤0.039                      | 0.312                       | 1.25                        | 2.5                         |
| Marbofloxacin       | ≤0.039            | 0.156             | ≤0.039–5      | ≤0.039–10   | ≤0.039                      | 1.25                        | 2.5                         | 5                           |
| Tetracyclines       |                   |                   |               |             |                             |                             |                             |                             |
| Oxytetracycline     | ≤0.25             | 4                 | ≤0.25–4       | 0.5–32      | ≤0.25                       | 4                           | 2                           | 16                          |
| Doxycycline         | ≤0.039            | 0.625             | ≤0.039–0.625  | 0.078–2.5   | 0.078                       | 0.625                       | 0.312                       | 2.5                         |
| Aminoglycoside      |                   |                   |               |             |                             |                             |                             |                             |
| Gentamicin          | ≤0.25             | 1                 | ≤0.25–0.5     | 0.5–2       | ≤0.25                       | 1                           | 0.5                         | 2                           |
| Aminocyclitol       |                   |                   |               |             |                             |                             |                             |                             |
| Spectinomycin       | 1                 | 4                 | ≤0.25–4       | 1–8         | 2                           | 4                           | 2                           | 4                           |
| Macrolides          |                   |                   |               |             |                             |                             |                             |                             |
| Tylosin             | ≤0.25             | 0.5               | ≤0.25–32      | ≤0.25–64    | 0.25                        | 0.5                         | ≤0.25                       | 0.5                         |
| Tilmicosin          | 2                 | 8                 | ≤0.25–>64     | 2–>64       | 2                           | 8                           | 4                           | 16                          |
| Tylvalosin          | ≤0.25             | ≤0.25             | ≤0.25–2       | ≤0.25–8     | ≤0.25                       | ≤0.25                       | ≤0.25                       | ≤0.25                       |
| Gamithromycin       | 1                 | 4                 | ≤0.25–64      | 1–>64       | 0.5                         | 4                           | 2                           | 8                           |
| Tulathromycin       | 1                 | 4                 | ≤0.25–>64     | 0.5–>64     | 0.5                         | 2                           | 1                           | 4                           |
| Lincosamide         |                   |                   |               |             |                             |                             |                             |                             |
| Lincomycin          | ≤0.25             | 1                 | ≤0.25–>64     | ≤0.25–>64   | ≤0.25                       | 0.5                         | ≤0.25                       | 1                           |
| Pleuromutilins      |                   |                   |               |             |                             |                             |                             |                             |
| Tiamulin            | ≤0.039            | 0.156             | ≤0.039–0.156  | 0.078–0.312 | ≤0.039                      | 0.156                       | 0.078                       | 0.156                       |
| Valnemulin          | ≤0.039            | ≤0.039            | ≤0.039        | ≤0.039      | ≤0.039                      | ≤0.039                      | ≤0.039                      | ≤0.039                      |
| Phenicol            |                   |                   |               |             |                             |                             |                             |                             |
| Florfenicol         | 1                 | 2                 | ≤0.125–2      | 1–4         | 1                           | 2                           | 2                           | 4                           |

https://doi.org/10.1371/journal.pone.0209030.t001
Synonymous substitutions were observed in genes associated with susceptibility to fluoroquinolones (gyrA, gyrB, parC and parE); however, only SNPs resulting in amino acid alterations were further examined in the present study. None of the amino acid changes in the genes gyrB and parE showed correlation with the defined MIC values. On the other hand, amino acid changes in the gyrA gene (Gly81Ala, Ala83Val and Glu87Gly) and in the parC gene (Ser80Phe, Ser80Tyr or Asp84Asn) correlated with decreased susceptibility of fluoroquinolones (S3 Table). Single alterations in the parC gene seem to have no crucial effect on fluoroquinolone susceptibility when initial MIC values are examined. On the other hand, at least 12-fold concentration difference is observed in the final MIC values against strains, which contain a single alteration in the parC gene. As opposed to the observed slight increase of MIC values of fluoroquinolones in association with the single substitution event in gene parC, double substitutions in genes parC and gyrA correlated with final MIC values higher than 2 μg/ml in all cases, with one exception (MycSu44). It is noteworthy, that the double substitutions in strain MycSu44 consisted of Ala83Val in gene gyrA and Asp84Asn in parC, while the rest of the strains showed various amino acid substitution types in gene gyrA but only the change of serine at amino acid
position 80 in gene parC. The one outlier strain (MycSu17) against which 2.5–5 μg/ml initial MIC values of fluoroquinolones were detected contained the double substitution combination Ser80Phe (in parC gene) with Ala83Val (in gyrA gene). Correlation was described between increased MIC values of macrolides and lincosamides against Mycoplasma species/ M. hyopneumoniae and SNPs in the 23S rRNA sequence [14,19]. A nucleotide substitution at the position A2059G was found in the outlier strain (MycSu18) showing extremely decreased susceptibility to macrolides and lincosamides (S3 Table). The observed SNPs in the strains originating from the same herds were consistent with one exception: the strains originating from Mezőtúr (MycSu7; 8 and 41), which also clustered into completely different sequence types according to earlier genotyping analysis [31] showed distinct susceptibility profiles and genetic alterations correlating with antibiotic susceptibility.

Discussion

Antibiotic susceptibility testing of porcine mycoplasmas is not performed routinely, because it is fastidious, time-consuming and requires special techniques and media [17]. Furthermore, the lack of official standards makes the interpretation of the results difficult. The Clinical and Laboratory Standards Institute (CLSI) has provided official breakpoints for certain antibiotics but only for human pathogen mycoplasmas [35] and the procedures and media vary according to each of the examined species [36].

Fluoroquinolones are potentially active antimicrobial agents against M. hyopneumoniae through inhibition of the bacterial DNA gyrase and topoisomerase IV enzymes [19,22]. In the present study, a broad range of MIC values was recorded with low MIC\textsubscript{50} value of enrofloxacin, similarly to previous results in other European publications in the last 20 years [11,13,34]. One of the examined strains (MycSu17) was inhibited by higher enrofloxacin concentration, the MIC value against this strain exceeded the unofficial breakpoint determined by Hannan et al. [11]. Similar observations have already been recorded with high MIC values in Thailand (≥2 μg/ml) and in Belgium (>1 μg/ml) [13,33], which forewarns the importance of susceptibility testing before choosing antibiotics for treatment. Although MIC\textsubscript{50} value of marbofloxacin against the studied strains was mostly in accordance with recent data, MIC\textsubscript{90} value against the Hungarian isolates was higher than those against Belgian, Spanish and British strains (0.5–1 μg/ml) [34].

No amino acid substitutions, correlating with increased MIC values, were observed in the genes gyrB and parE, corroborating earlier publications [18]. Although single amino acid substitutions in the parC gene (Ser80Phe, Ser80Tyr or Asp84Asn) showed correlation with increased MIC values of fluoroquinolones in earlier publications [15,18,19], the degree of increase seems to be negligible according to the initial MIC values detected in the present study. However, definite increase of MIC values was detected when double substitutions in parC and gyrA genes were described in the examined strains. The observed effect of the double substitutions is in accordance with previous findings of Vicca et al. [18]. Various combinations of amino acid changes were detected in the examined strains containing double substitutions in the genes gyrA and parC, defining a unique combination in the outlier strain (MycSu17). Moreover, new amino acid alterations (Glu87Gly and Gly81Ala) have been described in gyrA gene of M. hyopneumoniae in the present study, which had been observed only in M. bovis and M. gallisepticum before [23,24]. Factors influencing the degree of the decrease of susceptibility to fluoroquinolones, such as the type of amino acid changes or mechanisms are yet to be discovered. Although initial MIC values are advised to be taken into account in the interpretation of the results of antibiotic susceptibility tests [37], correlations between the amino acid substitutions and increased final MIC values were more defined in the current examinations and
better supported previous observations, which highlights the usefulness of determining final MIC values also.

The increasing susceptibility against fluoroquinolones is a notable problem, because these agents are important antibiotics for human therapy [38]. To maximize efficacy and reduce mutant selection in case of fluoroquinolones, the ratio of maximum serum concentration to the MIC (C\text{max}/MIC ratio) of equal or higher than 10 was proposed [39]. Marbofloxacin administered at 4 or 8 mg/kg intramuscularly resulted in 6.3 and 3.38 μg/ml C\text{max} in pigs [40] respectively, resulting in maximum activity against strains with MICs of 0.625 and 0.3125 μg/ml or lower in case of the two dosages, respectively.

Tetracyclines are frequently used to control *M. hyopneumoniae* infections, and they act by binding to the decoding centre of the small ribosomal subunit of the bacterium [4,41]. Most of the previous publications from Europe defined similar MIC\text{50} and MIC\text{90} values of oxytetracycline [11,13,34]; but higher MIC\text{50} and MIC\text{90} values of doxycycline were described against strains originating from Spain (1 μg/ml both) and Thailand (3.12 μg/ml and 6.25 μg/ml) than against the Hungarian isolates. According to other publications supported also by our results, tetracyclines are still active against *M. hyopneumoniae* despite of their long-standing usage in human and veterinary medicine [32,33].

The aminoglycoside gentamicin seems to be an effective antimicrobial agent against *M. hyopneumoniae*, as low MIC\text{50} and MIC\text{90} values were observed in the present study, similarly to earlier data [13,32]. Although MIC range of the aminocyclitol spectinomycin was broad similarly to the findings of a previous Spanish study, the MIC\text{50} and MIC\text{90} values were higher in the present study compared to Spanish and Belgian MIC values [13,32].

Macrolides are among the most frequently used antibiotics in the swine industry to treat *M. hyopneumoniae* infections [4]. Both 16-membered (tylosin, tilmicosin and tylvalosin) and 15-membered (tulathromycin and gamithromycin) macrolides were effective against the studied strains. However, the MIC value of tulathromycin against the type strain was three orders of magnitude higher, than in the literature [34]. The reason of the discrepancy might be a different passage number of the type strain, or the different medium/antibiotic solution used during the test. However, the MIC value of tulathromycin against the type strain did not exceed 16 μg/ml (a possible unofficial breakpoint according to other porcine respiratory pathogens [42]) in either case. In the current study, a slight increase of MIC\text{50} and MIC\text{90} values of macrolides was described compared to the literature [34], and extremely high MIC values against an outlier strain (MycSu18) was noted. According to the literature, nucleotide substitutions at the bases 2057–2059 of the 23S rRNA sequence play an important role in acquired resistance to macrolides [14,19,43]. Analysis of the 23S rRNA sequence of the strain MycSu18 revealed a nucleotide substitution A2059G (*E. coli* numbering), which was also described in macrolide and lincosamide resistant *M. bovis* strains before [24]. According to the habituation study of Hannan *et al.* [12] and the high MIC values presented in this study, emergence of macrolide-resistance could be a considerable problem, which was confirmed by earlier reported results from Belgium [13], Thailand [33] and Spain [32].

Lincomycin is also active against *M. hyopneumoniae*, but extremely high MIC values appear every now and then [13,32,33], like the outlier strain (MycSu18) in the present study. The reason of the decreased susceptibility can be the cross-resistance with macrolides, as reported in an earlier publication, which described decreasing susceptibility against tylosin and lincomycin in strains originating from a lincomycin-treated herd [13]. The simultaneously appearing change in susceptibility may lead back to the same mode of action of macrolides and lincosamides, inhibiting bacterial protein synthesis on the 50S ribosomal subunit [44].

Pleuromutilins are important antibiotics to control *M. hyopneumoniae* infections through inhibiting bacterial protein synthesis [45]. According to our results and other publications,
tiamulin seems to be one of the most effective antimicrobial agents against *M. hyopneumoniae* with low *in vitro* inhibitory concentrations \[11–13,32–34\]. Valnemulin is the most effective antibiotic against all of the studied strains, which supported the earlier published observations \[12,32,34\].

The chloramphenicol derivative florfenicol is an inhibitor of bacterial protein synthesis, used exclusively for veterinary purposes \[46\]. The moderate distribution of the MIC range and the relatively low MIC\(_{50}\) and MIC\(_{90}\) values of florfenicol, were similar to earlier observations from different parts of Europe and Thailand \[13,33,34\], and they may indicate that this antibiotic is an effective agent against *M. hyopneumoniae*.

*In vitro* MIC values do not necessarily correlate with the effectiveness of the antimicrobials *in vivo* and interpretation of the MIC distributions is difficult as *Mycoplasma* species with veterinary relevance do not have official clinical breakpoints \[34\]. Furthermore, strains with different antibiotic susceptibility can coexist within a herd \[33\]. PK/PD (pharmacokinetic-pharmacodynamic) analysis is an important tool to maximize *in vivo* antimicrobial activity \[47,48\]. Most of our results were in accordance with other results of the European region, this involves, that all the tested agents are most probably still suitable to control enzootic pneumonia. Nonetheless the results of this study may help veterinarians to choose the proper antimicrobial agent against *M. hyopneumoniae*. Although the isolation of *M. hyopneumoniae* strains is a time-consuming and fastidious process, the regularly accomplished antibiotic susceptibility testing of the swine herds should enable appropriate antibiotic usage during treatment. Furthermore, the development of PCR-based susceptibility tests based on SNPs correlating with changes in the MIC values, could improve diagnostics and treatment, similarly to antibiotic susceptibility testing in *M. bovis* \[24\].

**Conclusion**

This study provided current and relevant information about the antibiotic susceptibility profiles of *M. hyopneumoniae* strains circulating in Hungary and surrounding countries. Low MIC values of all the tested antibiotics were described against most of the studied *M. hyopneumoniae* strains, and the lowest MIC values were found in case of gentamicin, tylosin, tylvalosin, lincomycin, tiamulin and valnemulin. In certain cases, high MIC values of fluoroquinolones (MycSu17) or macrolides and lincomycin (MycSu18) were observed. Single or double amino acid substitutions in the genes gyrA (Gly81Ala, Ala83Val, Glu87Gly), parC (Ser80Phe, Ser80Tyr, Asp84Asn) and a SNP in the 23S rRNA sequence (A2059G) were also detected correlating with decreased antibiotic susceptibilities. Macrolides and fluoroquinolones are frequently used empirically as a first choice for the management of mycoplasmoses in livestock in Europe. The regular testing of the sensitivity profile of *M. hyopneumoniae*, the determination of herd specific MICs would promote the use of less critical antibacterials (e.g.: florfenicol, tetracyclines, pleuromutilins), and might contribute to the preservation of the critically important antibiotics (macrolides and fluoroquinolones) both for veterinary and human medicine.

**Supporting information**

**S1 Table.** Background data of *M. hyopneumoniae* strains and initial minimum inhibitory concentration (MIC) values (μg/ml) of 15 antimicrobials against the strains used in the study. Isolation data (Sample ID, Herd of origin and Date of isolation) and MIC values of enrofloxacin (EFX), marbofloxacin (MFX), oxytetracycline (OTC), doxycycline (DX), gentamicin (GTC), spectinomycin (SPC), tylosin (TYL), tilmicosin (TIL), tylvalosin (TVN), gamithromycin (GTM), tulathromycin (TTM), tiamulin (TIA), valnemulin (VAL), lincomycin
Antibiotic susceptibility testing of *Mycoplasma hyopneumoniae* field isolates from Central Europe

(LCM) and florfenicol (FFC) are presented. Abbreviations for herd of origin are: H-Hungary, CZ-Czech Republic, SK-Slovakia.

(S2 Table) **Background data of *M. hyopneumoniae* strains and final minimum inhibitory concentration (MIC) values (μg/ml) of 15 antimicrobials against the strains used in the study.** Isolation data (Sample ID, Herd of origin and Date of isolation) and MIC values of enrofloxacin (EFX), marbofloxacin (MFX), oxytetracycline (OTC), doxycycline (DX), gentamicin (GTC), spectinomycin (SPC), tylosin (TYL), tilmicosin (TIL), tyvalosin (TVN), gamithromycin (GTM), tulathromycin (TTM), tiamulin (TIA), valnemulin (VAL), lincomycin (LCM) and florfenicol (FFC) are presented. Abbreviations for herd of origin are: H-Hungary, CZ-Czech Republic, SK-Slovakia.

(S3 Table) **Initial and final minimum inhibitory concentration (MIC) ranges (μg/ml) of fluoroquinolones, macrolides and lincomycin against the examined *M. hyopneumoniae* isolates with the amino acid substitutions in the *gyrA* and *parC* genes and nucleotide substitutions in the 23S rRNA sequence.**

_Author Contributions_

**Data curation:** Miklós Gyuranecz.

**Formal analysis:** Kinga Mária Sulyok.

**Investigation:** Orsolya Felde, Veronika Hrivnák, Krisztián Kiss, Imre Biksi.

**Methodology:** Zsuzsa Kreizinger, Kinga Mária Sulyok, Miklós Gyuranecz.

**Project administration:** Veronika Hrivnák.

**Resources:** Miklós Gyuranecz.

**Supervision:** Miklós Gyuranecz.

**Writing – original draft:** Orsolya Felde, Zsuzsa Kreizinger.

**Writing – review & editing:** Kinga Mária Sulyok, Ákos Jerzsele, Miklós Gyuranecz.

**References**

1. Artiushin S, Minion FC. Arbitrarily primed PCR analysis of *Mycoplasma hyopneumoniae* field isolates demonstrates genetic heterogeneity. Int J Syst Evol Microbiol. 1996; 46:324–328.

2. Kobisch M, Friss NF. Swine mycoplasmoses. Rev Sci Tech. 1996; 15:1569–1605. PMID: 9190026

3. Maes D, Verdonck M, Deluyker H, de Kruijff A. Enzootic pneumonia in pigs. Vet Q. 1996; 18:104–109. [https://doi.org/10.1080/01652176.1996.9694628](https://doi.org/10.1080/01652176.1996.9694628) PMID: 8903144

4. Maes D, Segales J, Meyns T, Sibila M, Pieters M, Haesebrouck F. Control of *Mycoplasma hyopneumoniae* infections in pigs. Vet Microbiol. 2008; 126:297–309. [https://doi.org/10.1016/j.vetmic.2007.09.008](https://doi.org/10.1016/j.vetmic.2007.09.008) PMID: 17994089

5. Maes D, Sibila M, Kuhnert P, Segalés J, Haesebrouck F, Pieters M. Update on *Mycoplasma hyopneumoniae* infections in pigs: Knowledge gaps for improved disease control. Transbound Emerg Dis. 2017; [https://doi.org/10.1111/tbed.12677](https://doi.org/10.1111/tbed.12677) PMID: 28834294

6. Wyns H, Meyer E, Pleessers E, Watteyan A, De Baere S, De Backer P, et al. Pharmacokinetics of gamithromycin after intravenous and subcutaneous administration in pigs. Res Vet Sci. 2014; 96:160–163. [https://doi.org/10.1016/j.resvsc.2013.11.012](https://doi.org/10.1016/j.resvsc.2013.11.012) PMID: 24331718

7. Pallarés FJ, Lasa C, Roosen M, Ramis G. Use of tyvalosin in the control of porcine enzootic pneumonia. Vet Rec Open. 2015;
8. El Garch F, de Jong A, Simjee S, Moyaert H, Klein U, Ludwig C, et al. Monitoring of antimicrobial susceptibility of respiratory tract pathogens isolated from diseased cattle and pigs across Europe, 2009–2012: VetPath results. Vet Microbiol. 2016; 194:11–22. https://doi.org/10.1016/j.vetmic.2016.04.009 PMID: 27102206

9. Thacker EL, Thacker BJ, Boettcher TB, Jayappa H. Comparison of antibody production, lymphocyte stimulation, and protection induced by four commercial Mycoplasma hyopneumoniae bacterins. Swine Health Prod. 1998; 6:107–112.

10. McCormack WM. Susceptibility of mycoplasmas to antimicrobial agents: Clinical implications. Clin Infect Dis. 1993; 17:200–201.

11. Hannan PCT, Windsor GD, De Jong A, Schmeer N, Stegemann M. Comparative susceptibilities of various animal-pathogenic mycoplasmas to fluoroquinolones. Antimicrob Agents Chemother. 1997; 41:2037–2040. PMID: 9303412

12. Hannan PCT, Windsor HM, Ripley PH. In vitro susceptibilities of recent field isolates of Mycoplasma hyopneumoniae and Mycoplasma hyosynoviae to valnemulin (Econor), tiamulin and enrofloxacin and the in vitro development of resistance to certain antimicrobial agents in Mycoplasma hyopneumoniae. Res Vet Sci. 1997; 63:157–160. PMID: 9429250

13. Vicca J, Stakenborg T, Maes D, Butaye P, Peeters J, de Kruijff A, et al. In vitro susceptibilities of Mycoplasma hyopneumoniae field isolates. Antimicrob Agents Chemother. 2004; 48:4470–4472. https://doi.org/10.1128/AAC.48.11.4470-4472.2004 PMID: 15504886

14. Stakenborg T, Vicca J, Butaye P, Maes D, Minion FC, Peeters J, et al. Characterization of in vivo acquired resistance of Mycoplasma hyopneumoniae to macrolides and lincosamides. Microb Drug Resist. 2005; 11:290–294. https://doi.org/10.1089/mdr.2005.11.290 PMID: 16201934

15. Le Carrou J, Laurentie M, Kobisch M, Gautier-Bouchardon AV. Persistence of Mycoplasma hyopneumoniae in experimentally infected pigs after marbofloxacin treatment and detection of mutations in the parC gene. Antimicrob Agents Chemother. 2006; 50:1599–1606. https://doi.org/10.1128/AAC.01527-05 PMID: 16735552

16. Yamamoto K, Koshimizu K, Ogata M. In vitro susceptibility of Mycoplasma hyopneumoniae to antibiotics. Japanese J Vet Sci. 1986; 48:1–5.

17. Hannan PCT. Guidelines and recommendations for antimicrobial minimum inhibitory concentration (MIC) testing against veterinary mycoplasma species. Vet Res. 2000; 31:373–395. https://doi.org/10.1051/vetres:2000100 PMID: 10958240

18. Vicca J, Maes D, Stakenborg T, Butaye P, Minion F, Peeters J, et al. Resistance mechanism against fluoroquinolones in Mycoplasma hyopneumoniae field isolates. Microb Drug Resist. 2007; 13:166–170. https://doi.org/10.1089/mdr.2007.716 PMID: 17949302

19. Gautier-Bouchardon AV. Antimicrobial resistance in Mycoplasma spp. Microbiol Spectr. 2018; https://doi.org/10.1128/microbiolspec.ARBA-0030-2018 PMID: 3003864

20. Felde O, Kiss K, Biksi I, Jerzsele A, Gyuranecz M. A sertések Mycoplasma hyopneumoniae okozta tüdő gyulladására. (Pneumonia of pigs caused by Mycoplasma hyopneumoniae) Magy Állatorvosok Lapja. 2018; 140:337–348.

21. European Centre for Disease Prevention and Control, European Food Safety Authority, and European Medicines Agency, ECDC/EFSA/EMA first joint report on the integrated analysis of the consumption of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from humans and food-producing animals. EFSA J. 2015;

22. Hooper DC. Mechanisms of action and resistance of older and newer fluoroquinolones. Clin Infect Dis. 2000; 31(Supplement_2):S24–28.

23. Reinhardt AK, Kempf I, Kobisch M, Gautier-Bouchardon AV. Fluoroquinolone resistance in Mycoplasma gallisepticum: DNA gyrase as primary target of enrofloxacin and impact of mutations in topoisomerases on resistance level. J Antimicrob Chemother. 2002; 50:589–592. https://doi.org/10.1093/jac/dkf158 PMID: 12356806

24. Sulyok KM, Kreizinger Z, Wehmann E, Lysnyansky I, Bányaí K, Marton S, et al. Mutations associated with decreased susceptibility to seven antimicrobial families in field and laboratory-derived Mycoplasma bovis strains. Antimicrob Agents Chemother. 2017; https://doi.org/10.1128/AAC.01983-16 PMID: 27895010

25. Vester B, Douthwaite S. Macrolide Resistance conferred by base substitutions in 23S rRNA Antimicrob Agents Chemother. 2001; 45:1–12. https://doi.org/10.1128/AAC.45.1.1-12.2001 PMID: 11120937

26. Friis NF. Some recommendations concerning primary isolation of Mycoplasma suipneumoniae and Mycoplasma flocculare a survey. Nord Vet Med. 1975; 27:337–339. PMID: 10980111

27. Etheridge JR, Cottew GS, Lloyd LC. Isolation of Mycoplasma hyopneumoniae from lesions in experimentally infected pigs. Aust Vet J. 1979; 55:356–359. PMID: 533486
28. Mattsson JG, Bergström K, Wallgren P, Johansson KE. Detection of Mycoplasma hyopneumoniae in nose swabs from pigs by in vitro amplification of the 16S rRNA gene. J Clin Microbiol. 1995; 33:893–897. PMID: 7540629

29. Lauermann LH, Chilina AR, Closser JA, Johansen D. Avian Mycoplasma identification using polymerase chain reaction amplicon and restriction fragment length polymorphism analysis. Avian Dis. 1995; 39:804–811. PMID: 8719214

30. Kearse M, Moir R, Wilson A, Stones-Havas S, Cheung M, Sturrock S, et al. Geneious Basic: An integrated and extendable desktop software platform for the organization and analysis of sequence data. Bioinformatics. 2012; 28:1647–1649. https://doi.org/10.1093/bioinformatics/bts199 PMID: 22543367

31. Felde O, Kreizinger Z, Sulyok KM, Marton S, Bányaí K, Korbuly K, et al. Genotyping Mycoplasma hyopneumoniae isolates based on multi-locus sequence typing, multiple-locus variable-number tandem repeat analysis and analysing gene p146. Vet Microbiol. 2018; 222:85–90. https://doi.org/10.1016/j.vetmic.2018.07.004 PMID: 30080678

32. Tavío MM, Poveda C, Assunção P, Ramírez AS, Poveda JB. In vitro activity of tylvalosin against Spanish field strains of Mycoplasma hyopneumoniae. Vet Rec. 2014; https://doi.org/10.1136/vr.102458 PMID: 25185108

33. Thongkampoon P, Narongsak W, Kobayashi H, Pathanasophon P, Kishima M, Yamamoto K. In vitro susceptibility of Mycoplasma hyopneumoniae field isolates and occurrence of fluoroquinolone, macrolides and lincosycin resistance. J Vet Med Sci. 2013; 75:1067–1670. PMID: 23503167

34. Klein U, de Jong A, Moyaert H, El Garch F, Leon R, Richard-Mazet A, et al. Antimicrobial susceptibility monitoring of Mycoplasma hyopneumoniae and Mycoplasma bovis isolated in Europe. Vet Microbiol. 2017; 204:188–193. https://doi.org/10.1016/j.vetmic.2017.04.012 PMID: 28532800

35. Wayne P. Clinical and Laboratory Standards Institute (CLSI). Methods for antimicrobial susceptibility testing for human mycoplasmas; Approved guideline. CLSI document M43-A. 2011.

36. Waites KB, Duffy LB, Bébéar CM, Matlow A, Talkington DF, Kenny GE, et al. Standardized methods and quality control limits for agar and broth microdilution susceptibility testing of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum. J Clin Microbiol. 2012; 50:3542–3547. https://doi.org/10.1128/JCM.01439-12 PMID: 22915608

37. Kreizinger Z, Grózner D, Sulyok KM, Nilsson K, Hrivnák V, Benčina D, et al. Antibiotic susceptibility profiles of Mycoplasma synoviae strains originating from Central and Eastern Europe. BMC Vet Res. 2017; https://doi.org/10.1186/s12917-017-1266-2 PMID: 29149886

38. Collignon P, Powers JH, Chiller TM, Aidara-Kane A, Aarestrup FM. World Health Organization ranking of antimicrobials according to their importance in human medicine: A critical step for developing risk management strategies for the use of antimicrobials in food production animals. Clin Infect Dis. 2009; 49:132–141. https://doi.org/10.1086/599374 PMID: 19489713

39. Rodvoid KA, Neuhauser M. Pharmacokinetics and pharmacodynamics of fluoroquinolones. In: Pharmacotherapy: the journal of human pharmacology and drug therapy. 2001. 233S–252S.

40. Schneider M, Paulin A, Dron F, Woehrle F. Pharmacokinetics of marbofloxacin in pigs after intravenous and intramuscular administration of a single dose of 8 mg/kg: dose proportionality, influence of the age of the animals and urinary elimination. Vet Pharmacol Ther. 2014; 37:523–530. https://doi.org/10.1111/jvp.12125 PMID: 24666477

41. Nguyen F, Starosta AL, Arenz S, Sohmen D, Dönhöfer A, Wilson DN. Tetracycline antibiotics and resistance mechanisms. Biol Chem. 2014; 395:559–575. https://doi.org/10.1515/hsz-2013-0292 PMID: 24497223

42. Godinho KS. Susceptibility testing of tylvalosin: Interpretative breakpoints and susceptibility of field isolates. Vet Microbiol. 2008; 129:426–432. https://doi.org/10.1016/j.vetmic.2007.11.033 PMID: 18187275

43. Hansen JL, Ippolito JA, Ban N, Nissen P, Moore PB, Steitz TA. The structures of four macrolide antibiotics bound to the large ribosomal subunit. Mol Cell. 2002; 10:117–128. PMID: 12150912

44. Weisblum B. Insights into erythromycin action from studies of its activity as inducer of resistance. Antimicrob Agents Chemother. 1995; 39:797–805. PMID: 7785974

45. Poulsen SM, Karlsson M, Johansson LB, Vester B. The pleuromutilin drugs tiamulin and valnemulin bind to the RNA at the peptidyl transferase centre on the ribosome. Mol Microbiol. 2001; 41:1091–1099. PMID: 11555289

46. Priebe S, Schwarz S. In vitro activities of florfenicol against bovine and porcine respiratory tract pathogens. Antimicrob Agents Chemother. 2003; 47:2703–2705. https://doi.org/10.1128/AAC.47.8.2703-2705.2003 PMID: 12878547
47. Ahmad I, Huang L, Hao H, Sanders P, Yuan Z. Application of PK/PD modeling in veterinary field: Dose optimization and drug resistance prediction. Biomed Res Int. 2016; https://doi.org/10.1155/2016/5465678 PMID: 26989688

48. Somogyi Z, Karancsi Z, Jerzsele Á. Farmakokinetika/farmakodinámia (PK/PD) megközelítés az állatgyógyászatban: Irodalmi összefoglaló. (Pharmacokinetics/pharmacodynamics approach in the veterinary medicine: Literature review) Magy Állatorvosok Lapja. 2018; 14:37–46.